Heart Failure and Comorbidities (Chronic Kidney Disease, Diabetes, Obesity) Management: A Multidisciplinary Approach

心力衰竭及合并症(慢性肾病、糖尿病、肥胖)的管理:多学科协作模式

阅读:1

Abstract

BACKGROUND: Heart failure (HF) frequently coexists with chronic kidney disease (CKD), type 2 diabetes (T2D), and obesity, creating a complex clinical landscape that requires integrated, multidisciplinary management. The three main HF phenotypes - HF with reduced ejection fraction (EF ≤40%), mildly reduced ejection fraction (EF 41-49%), and preserved ejection fraction (EF ≥50%) - differ in their underlying pathophysiology and therapeutic approaches. Approximately 20-40% of patients with HF have T2D, 30-40% are obese (body mass index ≥30 kg/m2), and 45-63% have CKD. These comorbidities are interrelated through overlapping mechanisms such as insulin resistance, chronic inflammation, neurohormonal activation, and endothelial dysfunction, which amplify morbidity, mortality, and healthcare costs. SUMMARY: The interplay between HF, CKD, T2D, and obesity extends beyond hemodynamic compromise, influencing other frequent conditions such as anemia, sleep apnea, and atrial fibrillation. Addressing these interconnected comorbidities can yield cumulative benefits by improving both HF-specific and overall health outcomes. Data from recent clinical trials and observational studies indicate how these conditions modify risk, affect therapeutic response, and influence guideline-directed medical therapy. Optimal care involves timely recognition, evidence-based management, and coordination across specialties. Key contributors to care include cardiologists, primary care physicians, endocrinologists, nephrologists, pharmacists, dietitians, and mental health professionals. KEY MESSAGES: The coexistence of HF with CKD, T2D, and obesity constitutes a major clinical challenge with shared pathogenic pathways. Managing these comorbidities requires an integrated, multidisciplinary strategy to improve outcomes and quality of life. Barriers such as clinical inertia, polypharmacy, and socioeconomic disparities continue to impede effective therapy implementation. Enhanced collaboration and patient-centered care models are essential to optimize management in this high-risk population.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。